세계 종양내 암 치료 시장 규모는 2023년 2,026억 7,000만 달러에서 2024년부터 2031년까지 예측 기간 동안 10.33%의 연평균 복합 성장률(CAGR)로 성장하여 2031년에는 4,448억 2,000만 달러 규모로 성장할 것으로 예상됩니다.
미국암협회(American Cancer Society)에 따르면, 2023년 미국에서는 195만 8,310명이 새로 암에 걸리고 60만 9,820명이 사망할 것으로 추정되고 있습니다. 것으로 추산되고 있습니다.
예후를 개선하기 위해 환자 개개인의 요구사항과 유전자 프로파일에 따라 맞춤화할 수 있는 면역치료제의 채택이 증가하면서 시장 성장에 유리한 기회를 제공하고 있으며, mRNA 암 백신의 효능을 조사하기 위한 R&D 활동이 활발해지면서 시장 성장에 더욱 박차를 가하고 있습니다. 2023년에는 치료용 백신이 수술로 종양을 제거한 후 췌장암의 재발 위험을 감소시키는지 여부를 조사하기 위한 임상 2상 시험이 시작되었습니다. 이 임상시험은 메모리얼 슬론 케터링 암센터(Memorial Sloan Kettering Cancer Center, MSK)와 전 세계 약 80개 기관에서 260명의 환자를 등록할 예정입니다. 이 시험은 mRNA 접근법이 현재 표준 치료법보다 더 나은지 여부에 대한 통찰력을 얻을 수 있을 것으로 기대됩니다.
투자 증가로 인한 사업기회 도래
세계 여러 지역에서 암의 유병률이 증가함에 따라 일부 정부는 새로운 치료 솔루션에 대한 R&D 활동에 대한 투자를 늘리고 있습니다. 암은 환자와 그 가족뿐만 아니라 사회 생활에 큰 경제적 영향을 미치기 때문에 환자의 신속한 치료와 검사를 지원하는 다양한 조치에 대한 투자는 경제적 측면이 강합니다. 암 연구에 대한 투자를 통해 다양한 유형의 암을 조기에 발견할 수 있도록 지원하는 것을 목표로 하고 있습니다.
전략적 제휴로 시장 확대 지원
전략적 제휴 및 협력 관계를 통해 다양한 생명공학 기업 및 제약회사는 각자의 자원과 전문지식을 결합하여 아이디어, 경험 및 지식을 결합하여 개발 프로세스를 가속화할 수 있습니다. 암에 대한 TCR 기반 면역요법을 추진하기 위해 Medigene AG와 세계 전략적 제휴를 체결했습니다. 이 공동 연구에는 여러 표적 구조가 포함될 것으로 예상됩니다.
세계 종양내 암 치료 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
Global intratumoral cancer therapies market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 202.67 billion in 2023 to USD 444.82 billion in 2031F. The growing prevalence of cancer in various regions across the globe, expansion of the pharmaceutical industry, and rising research and development activities are bolstering the market growth. As per the American Cancer Society, 1,958,310 new cases and 609,820 deaths related to cancer were estimated to occur in the United States in 2023.
The growing adoption of immunotherapy drugs that can be tailored to the individual requirements of the patients and customized to their genetic profile for improving outcomes is providing lucrative growth opportunities to the market. Increasing research and development activities for investigating the efficacy of mRNA cancer vaccines is further supporting the market expansion. In 2023, a phase 2 clinical trial was opened to investigate whether therapeutic vaccines reduce the risk of return of pancreatic cancer after the removal of tumors by surgery. The study is expected to enroll 260 patients at Memorial Sloan Kettering Cancer Center (MSK) and approximately 80 sites across the globe. The trial will be open to individuals who recently received pancreatic cancer diagnosis and who have not yet had treatments including radiation therapy, immunotherapy, and chemotherapy or surgery. During phase 1 the vaccine was well tolerated by most patients, with phase 2 expected to offer clarity on the vaccine and various potential benefits. The trial is expected to offer insights into whether the mRNA approach performs better as compared to the current standards of the treatment.
Increasing Investments Anticipated to Offer Opportunities
Due to the growing prevalence of cancer in various regions across the globe, several governments are increasing investment in research and development activities for novel treatment solutions. Cancer has a significant economic impact on the lives of the patients and their families as well as the society, therefore there is a strong economic front for investing in various measures that will support the faster treatment and testing of patients. By investing in cancer research, they aim to support early detection of different types of cancers. For 2023, the American Institute for Cancer Research joined One Voice Against Cancer for requesting USD 49 billion in base funding for the National Institutes of Health.
Furthermore, various leading market players are investing in cancer research activities. According to Novartis India MD, the company invests 20% of its revenue towards research activities, including cancer research. With the help of dedicated research activities, the recognition and unraveling of cancer complexities will become much easier.
Strategic Collaborations Support Market Expansion
Through strategic partnerships and collaborations different biotechnology and pharmaceutical companies can pool their resources and expertise to combine their ideas, experience, and knowledge for fast-tracking the development process. In February 2022, BioNTech SE entered a global strategic partnership with Medigene AG to advance TCR-based immunotherapies against cancer. The research collaboration is expected to encompass several target structures. BioNTech SE is expected to hold exclusive worldwide commercialization rights and will be responsible for developing TCR therapies that result from the collaboration.
Amgen Inc., one of the leading American multinational biopharmaceutical companies committed to easing patient suffering by manufacturing, delivering, discovering, and developing innovative human therapeutics launched Amgen Partners of Choice. The network aims to bring together the company's clinical leaders and research and development experts from eight research centers around the globe. The network expects to create various collaboration channels to expedite the transformational programs that are focused on selected tumor types and disease areas.
North America Accounts for Significant Market Share
The strong presence of various leading market players, the increasing prevalence of cancer in the region, and rising investments in research and development activities are supporting the expansion of the market in the region. According to the Canadian Cancer Society, it was estimated that there would be 239,100 new cancer cases and 86,700 cancer-related deaths in Canada in 2023. Increasing public-private research collaborations are expected to offer the advancement of new therapies, supporting the market expansion in North America. For instance, the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration, is expected to facilitate uniform and systemic clinical testing of biomarkers for advancing the understanding of resistance to immunotherapies and mechanisms of treatment response.
Meanwhile, Europe is expected to witness significant growth in the coming years. The growth can be attributed to the rising research and development activities by the regional market players. Sanofi is conducting an interventional study to determine maximum administered dose or maximum tolerated dose and tolerability and safety of SAR441000 when administered intratumorally. The study is estimated to conclude in February 2024.
Rising Incidences of Lung Cancer Support Market Growth
According to the World Health Organization (WHO) lung cancer is the leading cause of cancer related to deaths across the globe and smoking is the leading cause of lung cancer, resulting in approximately 85% of all cases. The growth of the smoking populace is one of the major factors bolstering the demand for lung cancer therapies. Current technologies provide two approaches for intratumoral therapy in lung cancer, namely percutaneous and bronchoscopic. Bronchoscopic approaches are more suitable for tumors that grow deeper in the lungs and are more likely to obstruct or crush larger airways whereas percutaneous approaches are used for treating peripheral lung tumors that are present near the chest wall. Various research activities are underway to evaluate the efficacy of bronchoscopic intratumoral injection. For instance, a team of researchers from Hiser Medical Center of Qingdao, Shandong, China is conducting a study to evaluate the adverse reactions and therapeutic effects of cisplatin and endostar in patients suffering from lung squamous cell carcinoma.
Checkpoint Inhibitors Account for Significant Market Share
Due to various benefits associated with checkpoint inhibitors, the segment is anticipated to account for a significant share of the market over the forecast period. Rising product approvals by different regulatory bodies including FDA is further supporting the segmental growth. In 2023, GlaxoSmithKline Pharmaceuticals Ltd. won the first PD-1 approval.
Jemperli was cleared as an add-on for patients undergoing chemotherapy with recurrent or primary advanced endometrial cancer. For being eligible for the therapy, the tumor of the patient must be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). In phase 3 RUBY trial, it was observed that the addition of Jemperli to chemotherapy reduced death or risk of progression by 72% among patients with mismatch repair deficient or microsatellite instability-high tumors, while showing a progression-free survival improvement of 24%.
Future Market Scenario (2024 - 2031F)
Intratumoral immunotherapy is expected to bolster the effectiveness of cancer immunotherapies across a broad spectrum of malignancies. Addressing the barriers to intratumoral delivery can aid in maximizing the effectiveness of these therapies. Abundant opportunities are available to support the integration of novel biomaterials for providing sustained release and improved delivery of immunotherapies within tumors.
With the help of continuous advancements towards the development of intratumoral drug-releasing interventional implants and devices that facilitate tumor approach, intratumoral nanoDDS administrations are expected to offer a suitable alternative to conventional systemic drug delivery.
Key Players Landscape and Outlook
Key participants in the intratumoral cancer therapies market are GlaxoSmithKline Pharmaceuticals Ltd., BioNTech SE, Pfizer, Inc., F. Hoffmann-La Roche Ltd., and Amgen Inc. Increasing investments towards research and development activities and strategic collaborations are supporting the market expansion.
In 2023, BioNTech SE announced a partnership with the United Kingdom government to provide personalized mRNA cancer immunotherapies to up to 10,000 patients by 2030. The multi-year collaboration is expected to focus on cancer immunotherapies and the expansion of BioNTech's footprint in the country. The company aims to roll out and design randomized clinical trials with the potential for registration for the personalized mRNA cancer immunotherapies provided by the company in the United Kingdom.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work